![Richa Poddar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Richa Poddar worked as the Chief Commercial Officer at Agios Pharmaceuticals, Inc. from 2021 to 2022.
Prior to that, she worked as the Head of Marketing at Clovis Oncology, Inc. She holds a graduate degree from Keck Graduate Institute of Applied Life Sciences and an undergraduate degree from the University of Pune.
Precedenti posizioni note di Richa Poddar
Società | Posizione | Fine |
---|---|---|
AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 31/12/2022 |
CLOVIS ONCOLOGY, INC. | Vendite & Marketing | - |
Formazione di Richa Poddar
University of Pune | Undergraduate Degree |
Keck Graduate Institute of Applied Life Sciences | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
AGIOS PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 1 |
---|---|
Clovis Oncology, Inc.
![]() Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Richa Poddar